Profile

Karl-Erik Andersson, M.D., Ph.D.

Karl-Erik Andersson, M.D., Ph.D.

Professor, Institute for Regenerative Medicine
Physiology & Pharmacology
Urology
Molecular Medicine
Contact Information
Office:
336-716-2011
Email: keanders@wakehealth.edu
Education & Training
  MDLund University Fac Med-Sweden1968
Karl-Erik Andersson, M.D., Ph.D.

Karl-Erik Andersson, M.D., Ph.D.

Professor, Institute for Regenerative Medicine
Physiology & Pharmacology
Urology
Molecular Medicine
Contact Information
Office:
336-716-2011
Email: keanders@wakehealth.edu
Recent Publications
Gratzke C, Streng T, Stief CG, Alroy I, Limberg BJ, Downs TR, Rosenbaum JS, Hedlund P, Andersson K-E. Cannabinor, a selective cannabinoid-2 receptor agonist, improves bladder emptying in rats with partial urethral obstruction. J Urol. 2011; 185(2):731-736.


Campeau L, Gorbachinsky I, Ziegler JT, Langefeld CD, Andersson KE, Rohozinski J, Badlani G. Comparison of MMP-1 enzymatic activity and TIMP-1 inhibition in women with pelvic organ prolapse [abstract]. Neurourol Urodyn. 2011; 30(2):240-241.


Andersson KE. Muscarinic acetylcholine receptors in the urinary tract. Handb Exp Pharmacol. 2011; 202():319-344.


Abdel-Hamid IA, Andersson KE, Salonia A. Exploration of therapeutic targets for sexual dysfunctions: lessons learned from the failed stories. Expert Opin Ther Targets. 2011; 15(3):325-340.


Aizawa N, Igawa Y, Andersson K-E, Iijima K, Nishizawa O, Wyndaele J-J. Effects of intravesical instillation of ATP on rat bladder primary afferent activity and its relationship with capsaicin-sensitivity. Neurourol Urodyn. 2011; 30(1):163-168.


Andersson K-E, de Groat WC, McVary KT, Lue TF, Maggi M, Roehrborn CG, Wyndaele JJ, Melby T, Viktrup L. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn. 2011; 30(3):292-301.


Andersson K-E. Antimuscarinic mechanisms and the overactive detrusor: an update. Eur Urol. 2011; 59(3):377-386.


Kurizaki Y, Ishizuka O, Imamura T, Ichino M, Ogawa T, Igawa Y, Nishizawa O, Andersson K-E. Relation between expression of alpha1-adrenoceptor mRNAs in bladder mucosa and urodynamic findings in men with lower urinary tract symptoms. Scand J Urol Nephrol. 2011; 45(1):15-19.


Soler R, Fullhase C, Santos C, Andersson K-E. Development of bladder dysfunction in a rat model of dopaminergic brain lesion. Neurourol Urodyn. 2011; 30(1):188-193.


Thuroff JW, Abrams P, Andersson K-E, Artibani W, Chapple CR, Drake MJ, Hampel C, Neisius A, Schroder A, Tubaro A. EAU guidelines on urinary incontinence. Eur Urol. 2011; 59(3):387-400.


Russo A, Castiglione F, Salonia A, Benigni F, Andersson KE, Hedlund P. Effects by the GNRH antagonist ganirelix on normal micturition and PGE2-induced detrusor overactivity in conscious female rats [abstract]. Eur Urol Suppl. 2011; 10(2):256-257.


Russo A, Castiglione F, Salonia A, Benigni F, Rigatti P, Montorsi F, Andersson K-E, Hedlund P. Effects of the gonadotropin-releasing hormone antagonist ganirelix on normal micturition and prostaglandin E2-induced detrusor overactivity in conscious female rats. Eur Urol. 2011; 59(5):868-874.


Streng T, Andersson KE, Hedlund P, Gratzke C, Baroni E, D'Ambrosio D, Benigni F. Elocalcitol improves effects by tolterodine in rats with partial urethral obstruction [abstract]. Eur Urol Suppl. 2011; 10(2):181-182.


Andersson K-E, Soler R, Fullhase C. Rodent models for urodynamic investigation. Neurourol Urodyn. 2011; 30(5):636-646.


Kanai A, Wyndaele J-J, Andersson K-E, Fry C, Ikeda Y, Zabbarova I, De Wachter S. Researching bladder afferents--determining the effects of beta3-adrenergic receptor agonists and botulinum toxin type-A. Neurourol Urodyn. 2011; 30(5):684-691.


Strittmatter F, Gratzke C, Weinhold P, Steib CJ, Hartmann AC, Schlenker B, Andersson K-E, Hedlund P, Stief CG, Hennenberg M. Thromboxane A2 induces contraction of human prostate smooth muscle by Rho kinase- and calmodulin-dependent mechanisms. Eur J Pharmacol. 2011; 650(2-3):650-655.


van Koeveringe GA, Vahabi B, Andersson KE, Kirschner-Herrmans R, Oelke M. Detrusor underactivity: a plea for new approaches to a common bladder dysfunction. Neurourol Urodyn. 2011; 30(5):723-728.


Nielsen JS, Rode F, Rahbek M, Andersson K-E, Ronn LC, Bouchelouche K, Nordling J, Bouchelouche P. Effect of the SK/IK channel modulator 4,5-dichloro-1,3-diethyl-1,3-dihydro-benzoimidazol-2-one (NS4591) on contractile force in rat, pig and human detrusor smooth muscle. BJU Int. 2011; 108(5):771-777.


Bharadwaj S, Liu G, Shi Y, Markert C, Andersson K-E, Atala A, Zhang Y. Characterization of urine-derived stem cells obtained from upper urinary tract for use in cell-based urological tissue engineering. Tissue Eng Part A. 2011; 17(15-16):2123-2132.


Andersson K-E, Campeau L, Olshansky B. Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction. Br J Clin Pharmacol. 2011; 72(2):186-196.


Aizawa N, Iijima K, Rosenbaum JS, Downs TR, Igawa Y, Andersson K-E, Wyndaele J-J. Comparison of the effects of oestrogen deficiency and old age on primary bladder afferent activity and voiding behaviour in the ageing female rat. BJU Int. 2011; 108(2B):E10-E16.


Bauer RM, Strittmatter F, Gratzke C, Gottinger J, Schlenker B, Reich O, Stief CG, Hedlund P, Andersson K-E, Hennenberg M. Coupling of alpha1-adrenoceptors to ERK1/2 in the human prostate. Urol Int. 2011; 86(4):427-433.


Thuroff JW, Abrams P, Andersson K-E, Artibani W, Chapple CR, Drake MJ, Hampel C, Neisius A, Schroder A, Tubaro A. [EAU guidelines on urinary incontinence] [Spanish]. Actas Urol Esp. 2011; 35(7):373-388.


Andersson K-E, Abdel-Hamid IA. Therapeutic targets for premature ejaculation. Maturitas. 2011; 70(1):26-33.


Campeau L, Gorbachinsky I, Badlani GH, Andersson KE. Pelvic floor disorders: linking genetic risk factors to biochemical changes. BJU Int. 2011; 108(8):1240-1247.


Hennenberg M, Strittmatter F, Walther S, Hedlund P, Andersson K-E, Stief CG, Schlenker B, Gratzke C. Alpha 1-adrenoceptor activation induces phosphorylation of beta 2-adrenoceptors in human prostate tissue. BJU Int. 2011; 108(6):922-928.


Andersson K-E. Drugs and future candidates. Can Urol Assoc J. 2011; 5(5 Suppl 2):S131-S133.


Fullhase C, Soler R, Westerling-Andersson K, Andersson K-E. Beta3-adrenoceptors in the rat sacral spinal cord and their functional relevance in micturition under normal conditions and in a model of partial urethral obstruction. Neurourol Urodyn. 2011; 30(7):1382-1387.


Mangera A, Andersson K-E, Apostolidis A, Chapple C, Dasgupta P, Giannantoni A, Gravas S, Madersbacher S. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of Botox (onabotulinumtoxinA) and Dysport (abobotulinumtoxinA). Eur Urol. 2011; 60(4):784-795.


Andersson K-E. Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction. Pharmacol Rev. 2011; 63(4):811-859.


Jin L-H, Andersson K-E, Han J-U, Kwon Y-H, Park C-S, Shin H-Y, Yoon S-M, Lee T. Persistent detrusor overactivity in rats after relief of partial urethral obstruction. Am J Physiol Regul Integr Comp Physiol. 2011; 301(4):R896-904.


Gratzke C, Christ GJ, Stief CG, Andersson K-E, Hedlund P. Localization and function of cannabinoid receptors in the corpus cavernosum: basis for modulation of nitric oxide synthase nerve activity. Eur Urol. 2010; 57(2):342-349.


Andersson K-E. Detrusor myocyte activity and afferent signaling. Neurourol Urodyn. 2010; 29(1):97-106.


Andersson K-E. Re: Spontaneous release of acetylcholine from autonomic nerves in the bladder [editorial commentary]. Eur Urol. 2010; 57(1):171-176.


Soler R, Fullhase C [Fuellhase C], Lu B, Bishop CE, Andersson K-E. Bladder dysfunction in a new mutant mouse model with increased superoxide--lack of nitric oxide?. J Urol. 2010; 183(2):780-785.


Gratzke C, Weinhold P, Reich O, Seitz M, Schlenker B, Stief CG, Andersson K-E, Hedlund P. Transient receptor potential A1 and cannabinoid receptor activity in human normal and hyperplastic prostate: relation to nerves and interstitial cells. Eur Urol. 2010; 57(5):902-910.


Chen Z, Ishizuka O, Imamura T, Aizawa N, Kuriazki Y, Igawa Y, Nishizawa O, Andersson K-E. Stimulation of skin menthol receptors stimulates detrusor activity in conscious rats. Neurourol Urodyn. 2010; 29(3):506-511.


Kanai A, Andersson K-E. Bladder afferent signaling: recent findings. J Urol. 2010; 183(4):1288-1295.


Weinhold P, Gratzke C, Streng T, Stief C, Andersson K-E, Hedlund P. TRPA1 receptor induced relaxation of the human urethra involves TRPV1 and cannabinoid receptor mediated signals, and cyclooxygenase activation. J Urol. 2010; 183(5):2070-2076.


Gratzke C, Streng T, Stief CG, Downs TR, Alroy I, Rosenbaum JS, Andersson K-E, Hedlund P. Effects of cannabinor, a novel selective cannabinoid 2 receptor agonist, on bladder function in normal rats. Eur Urol. 2010; 57(6):1093-1100.


McKenzie P, Rohazinski J, Vishwajit S, Andersson K-E, Badlani G. Mmp-1 promoter variant is associated with stress urinary incontinence and pelvic organ prolapse [abstract]. Neurourol Urodyn. 2010; 29(2):255-256.


Russo A, Castiglione F, Andersson KE, Gustafsson JA, Hedlund P. Nitric oxide-, CGMP- & PGK1-mediated relaxation of the mouse vagina is coupled to the alpha estrogen receptor [abstract]. J Sex Med. 2010; 7(Suppl 3):130.


Christ GJ, Melman A, Williams K, Aboushwareb T, Zhao WX, Kaplan J, Anderson K-E [sic] [Andersson K-E]. Nonhuman primates as a model for translational research on atherosclerosis-related vascular disease and erectile dysfunction [abstract]. J Sex Med. 2010; 7(Suppl 1):46.


Fullhase C, Soler R, Gratzke C, Brodsky M, Christ GJ, Andersson K-E. Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction. BJU Int. 2010; 106(2):287-293.


Zhao W, Aboushwareb T, Turner C, Mathis C, Bennett C, Sonntag WE, Andersson K-E, Christ G. Impaired bladder function in aging male rats. J Urol. 2010; 184(1):378-385.


Andersson K-E, Sarawate C, Kahler KH, Stanley EL, Kulkarni AS. Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder. BJU Int. 2010; 106(2):268-274.


Fullhase C, Soler R, Gratzke C, Brodsky M, Christ GJ, Andersson K-E. Spinal effects of the fesoterodine metabolite 5-hydroxymethyl tolterodine and/or doxazosin in rats with or without partial urethral obstruction. J Urol. 2010; 184(2):783-789.


Burmeister D, AbouShwareb T, Tan J, Link K, Andersson K-E, Christ G. Early stages of in situ bladder regeneration in a rodent model. Tissue Eng Part A. 2010; 16(8):2541-2551.


Jin L-H, Andersson K-E, Kwon Y-H, Yoon S-M, Lee T. Selection of a control rat for conscious spontaneous hypertensive rats in studies of detrusor overactivity on the basis of measurement of intra-abdominal pressures. Neurourol Urodyn. 2010; 29(7):1338-1343.


Soler R, Fullhase C, Hanson A, Andersson K, Santos C. Effect of amniotic fluid and bone marrow stem cell therapy on bladder dysfunction in a Parkinson's disease model [abstract]. Int Urogynecol J. 2010; 21(Suppl 1):S384-S385.


Andersson K-E, Gratzke C, Hedlund P. The role of the transient receptor potential (TRP) superfamily of cation-selective channels in the management of the overactive bladder. BJU Int. 2010; 106(8):1114-1127.


Burnett AL, Goldstein I, Andersson KE, Argiolas A, Christ G, Park K, Xin ZC. Future sexual medicine physiological treatment targets. J Sex Med. 2010; 7(10):3269-3304.


Montorsi F, Adaikan G, Becher E, Giuliano F, Khoury S, Lue TF, Sharlip I, Althof SE, Andersson KE, Brock G, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med. 2010; 7(11):3572-3588.


Streng T, Santti R, Andersson K-E. Voiding effects mediated by alpha2-adrenoceptors in the anaesthetized male rat. BJU Int. 2010; 106(10):1546-1549.


Limberg BJ, Andersson K-E, Kullmann FA, Burmer G, de Groat WC, Rosenbaum JS. Beta-adrenergic receptor subtype expression in myocyte and non-myocyte cells in human female bladder. Cell Tissue Res. 2010; 342(2):295-306.


Ekman M, Andersson K-E, Arner A. Signal transduction pathways of muscarinic receptor mediated activation in the newborn and adult mouse urinary bladder. BJU Int. 2009; 103(1):90-97.


Jin L-H, Andersson K-E, Kwon Y-H, Park C-S, Yoon S-M, Lee T. Substantial detrusor overactivity in conscious spontaneously hypertensive rats with hyperactive behaviour. Scand J Urol Nephrol. 2009; 43():3-7.


Vishwajit S, Anderson KE [sic] [Andersson KE]. Terminology of lower urinary tract symptoms. Helpful or confusing?. ScientificWorldJournal. 2009; 9():17-22.


Abdel-Hamid IA, Jannini EA, Andersson KE. Premature ejaculation: focus on therapeutic targets. Expert Opin Ther Targets. 2009; 13(2):175-193.


Gratzke C, Streng T, Park A, Christ G, Stief CG, Hedlund P, Andersson K-E. Distribution and function of cannabinoid receptors 1 and 2 in the rat, monkey and human bladder. J Urol. 2009; 181(4):1939-1948.


Gratzke C, Streng T, Waldkirch E, Sigl K, Stief C, Andersson K-E, Hedlund P. Transient receptor potential A1 (TRPA1) activity in the human urethra--evidence for a functional role for TRPA1 in the outflow region. Eur Urol. 2009; 55(3):696-704.


Chen Z, Ishizuka O, Imamura T, Aizawa N, Igawa Y, Nishizawa O, Andersson K-E. Role of alpha1-adrenergic receptors in detrusor overactivity induced by cold stress in conscious rats. Neurourol Urodyn. 2009; 28(3):251-256.


Soler R, Fullhase C [Fuellhase C], Santos CC, Vishwajit S, Badlani GH, Andersson K-E. Bladder dysfunction in an acute experimental model of unilateral dopaminergic neurons lesion [abstract]. J Urol. 2009; 181(4 Suppl):336.


Vishwajit S, Rohozinski J, Andersson K-E, Badlani GH. Association of MMP1 promoter variant with stress urinary incontinence and pelvic organ prolapse in women [abstract]. J Urol. 2009; 181(4 Suppl):481.


Eberli D, Andersson KE, Yoo JJ, Atala A. A canine model of irreversible urethral sphincter insufficiency. BJU Int. 2009; 103(2):248-253.


Fuellhase C, Soler R, Andersson KE, Atala A, Yoo JJ. Generation of organized bladder tissue constructs using a novel hybrid printing system [abstract]. Eur Urol Suppl. 2009; 8(4):186.


Fullhase C [Fuellhase C], Soler R, Lu B, Bishop CE, Andersson KE. Increased levels of superoxide ions affects bladder function in a new mutant mouse model [abstract]. Eur Urol Suppl. 2009; 8(4):176.


Gratzke C, Weinhold P, Reich O, Stief CG, Andersson KE, Hedlund P. Distribution and function of transient receptor potential ion channel A1 and cannabinoid receptors in the human prostate [abstract]. Eur Urol Suppl. 2009; 8(4):190.


Gratzke C, Weinhold P, Selwood D, Stief CG, Andersson KE, Hedlund P. Distribution of the G-protein-coupled receptor 55 (GPR55) in the rat bladder and urodynamic effects of a selective GPR55-agonist in conscious rats [abstract]. Eur Urol Suppl. 2009; 8(4):271.


Soler R, Fuellhase C, Andersson KE, Yoo JJ. The effect of lamina propria cells on the growth of urothelial and smooth muscle cells [abstract]. Eur Urol Suppl. 2009; 8(4):188.


Streng T, Hedlund H, Svalheim S, Talo A, Solend CM, Andersson KE, Hedlund P. Bladder electrical activity during cystometry: application from rat to human [abstract]. Eur Urol Suppl. 2009; 8(4):243.


Weinhold P, Hedlund P, Reich O, Stief CG, Andersson KE, Gratzke C. Transient receptor potential A1 (TRPA1) agonists decrease nerve-mediated responses of the human ureter [abstract]. Eur Urol Suppl. 2009; 8(4):206.


Weinhold P, Gratzke C, Streng T, Andersson KE, Hedlund P. TRPA1-receptor-induced relaxation of the human urethra involves TRPV1-and cannabinoid-receptor-mediated signals and activation of cyclooxygenases [abstract]. Eur Urol Suppl. 2009; 8(4):270.


Andersson KE, Chapple CR, Cardozo L, Cruz F, Hashim H, Michel MC, Tannenbaum C, Wein AJ. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol. 2009; 19(4):380-394.


Zhao W, Sato Y, Melman A, Andersson KE, Christ G. Metrics for evaluation of age-related changes in erectile capacity in a rodent model. J Sex Med. 2009; 6(7):1885-1892.


Ekman M, Andersson K-E, Arner A. Receptor-induced phasic activity of newborn mouse bladders is inhibited by protein kinase C and involves T-type Ca2+ channels. BJU Int. 2009; 104(5):690-697.


Imamura T, Ishizuka O, Zhong C, Ogawa T, Nakayama T, Kurizaki Y, Tanabe T, Nishizawa O, Andersson K-E. An extract (THC-002) of Ba-Wei-Die-Huang-Wan inhibits expression of tachykinins, and P2X3 and TRPV1 receptors, and inhibits ATP-induced detrusor overactivity in spontaneously hypertensive rats. Neurourol Urodyn. 2009; 28(6):529-534.


Aboushwareb T, Zhou G, Deng F-M, Turner C, Andersson K-E, Tar M, Zhao W, D'Agostino R Jr, Sun T-T, Christ GJ, et al. Alterations in bladder function associated with urothelial defects in uroplakin II and IIIa knockout mice. Neurourol Urodyn. 2009; 28(8):1028-1033.


Kim J, Asche C, Kahler K, Kulkarni A, Andersson KE. Assessment of cardiovascular (CV) comorbidity in patients with overactive bladder (OAB) [abstract]. Pharmacoepidemiol Drug Saf. 2009; 18(Suppl 1):S241-S242.


Aizawa N, Iijima K, Rosenbaum J, Downs TR, Igawa Y, Andersson K, Wyndaele JJ. Effects of estrogen deficiency and its replacement on voiding behaviour and primary bladder afferent activity in the rat [abstract]. Neurourol Urodyn. 2009; 28(7):800-802.


Burmeister D, AbouShwareb T, Andersson K, Christ G. Establishing a rodent model for characterization of natural in vivo bladder regeneration [abstract]. Neurourol Urodyn. 2009; 28(7):739-741.


Ishizuka O, Chen Z, Imamura T, Aizawa N, Kurizaki Y, Igawa Y, Nishizawa O, Andersson K. Stimulation of cold stress skin receptor: transient receptor potential melastatin 8 (TRPM8) causes sudden urinary frequency in normal conscious rats [abstract]. Neurourol Urodyn. 2009; 28(7):750-752.


Soler R, Fuellhase C, Lu B, Bishop C, Andersson K. Bladder dysfunction in a new animal model of increased levels of superoxide ions [abstract]. Neurourol Urodyn. 2009; 28(7):809-810.


Christ GJ, Andersson K-E, Williams K, Zhao W, D'Agostino R Jr, Kaplan J, Aboushwareb T, Yoo J, Calenda G, Davies KP, et al. Smooth-muscle-specific gene transfer with the human Maxi-K channel improves erectile function and enhances sexual behavior in atherosclerotic cynomolgus monkeys. Eur Urol. 2009; 56(6):1055-1066.


Abdel-Hamid IA, Andersson KE. Pharmacogenetics and pharmacogenomics of sexual dysfunction: current status, gaps and potential applications. Pharmacogenomics. 2009; 10(10):1625-1644.


Andersson KE. Pharmacotherapy of the overactive bladder. Discov Med. 2009; 8(42):118-124.


Andersson KE. When and how do antimuscarinics work in bladder dysfunction, and what's coming up in treatment? [abstract]. Eur J Neurol. 2009; 16(Suppl 3):630.


Werkstrom V, Hedlund P, Lee T, Andersson K-E. Vardenafil-induced relaxation and cyclic nucleotide levels in normal and obstructed rat urinary bladder. BJU Int. 2009; 104(11):1740-1745.


Russo A, Castiglione F, Anderson KE [sic] [Andersson KE], Gustafsson JA, Hedlund P. Lack of estrogen receptor alpha alters nerve-mediated contraction and NO/cGMP-mediated relaxation of the mouse vagina [abstract]. J Sex Med. 2009; 6(Suppl 5):405-406.


Lee T, Andersson K-E, Streng T, Hedlund P. Simultaneous registration of intraabdominal and intravesical pressures during cystometry in conscious rats--effects of bladder outlet obstruction and intravesical PGE2. Neurourol Urodyn. 2008; 27(1):88-95.


Streng T, Axelsson HE, Hedlund P, Andersson DA, Jordt S-E, Bevan S, Andersson K-E, Hogestatt ED, Zygmunt PM. Distribution and function of the hydrogen sulfide-sensitive TRPA1 ion channel in rat urinary bladder. Eur Urol. 2008; 53(2):391-400.


Aboushwareb T, Burmeister D, Andersson KE, Christ GJ. Novel longitudinal studies of rat bladder regeneration [abstract]. Eur Urol Suppl. 2008; 7(3):266.


Christ GJ, Andersson K-E, Williams K, Zhao W, D'Agostino R, Kaplan J, Aboushwareb T, Yoo J, Davies K, Melman A. MAXI-K gene transfer with a smooth muscle specific promoter enhances erectile function and sexual behaviour in atherosclerotic cynomolgous monkeys [abstract]. Eur Urol. 2008; 7(3 Suppl):143.


Gratzke C, Christ GJ, Kaplan JR, Stief CG, Andersson KE, Badlani G. Chronic soy and phytoestrogen treatment leads to significant functional and morphological changes in the urethra of oophorectomized female non-human primates [abstract]. Eur Urol. 2008; 7(3 Suppl):315.


Gratzke C, Christ GJ, Kaplan JR, Andersson K-E, Badlani G. Chronic soy and phytoestrogen treatment leads to significant functional and morphological changes in the urethra of female non-human primates [abstract]. Neurourol Urodyn. 2008; 27(2):106.


Hipp JA, Hipp JD, Yoo JJ, Atala A, Andersson KE. Micro array analysis of bladder smooth muscle from patients with myelomeningocele [abstract]. Eur Urol. 2008; 7(3):229.


Hodges SJ, Zhou G, Deng F-M, Aboushwareb T, Turner C, Andersson K-E, Santago P, Case D, Sun T-T, Christ GJ. Voiding pattern analysis as a surrogate for cystometric evaluation in uroplakin II knockout mice. J Urol. 2008; 179(5):2046-2051.


Werkstrom V, Lee T, Hedlund P, Andersson KE. Vardenafil relaxes precontracted rat detrusor partially through urothelium-dependent mechanisms [abstract]. Eur Urol. 2008; 7(3 Suppl):264.


Zhao W, Machigal M, Turner C, Davies K, Melman A, Andersson KE, Christ GJ. Threshold gene transfer with hSlo enhances sildenafil-induced erectile responses in 2-month streptozotocin (STZ)-diabetic rats [abstract]. Eur Urol. 2008; 7(3 Suppl):217.


Lu B, Poirier C, Gaspar T, Gratzke C, Harrison W, Busija D, Matzuk MM, Andersson K-E, Overbeek PA, Bishop CE. A mutation in the inner mitochondrial membrane peptidase 2-like gene (Immp2l) affects mitochondrial function and impairs fertility in mice. Biol Reprod. 2008; 78(4):601-610.


Ney P, Pandita RK, Newgreen DT, Breidenbach A, Stohr T, Andersson K-E. Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo. BJU Int. 2008; 101(8):1036-1042.


Gomez-Pinilla PJ, Gomez MF, Sward K, Hedlund P, Hellstrand P, Camello PJ, Andersson K-E, Pozo MJ. Melatonin restores impaired contractility in aged guinea pig urinary bladder. J Pineal Res. 2008; 44(4):416-425.


Hipp JA, Hipp JD, Yoo JJ, Atala A, Andersson KE. Microarray analysis of bladder smooth muscle from patients with myelomeningocele. BJU Int. 2008; 102(6):741-746.


Andersson K-E. How many drugs for LUTS due to BPH are too many? [editorial]. J Urol. 2008; 180(3):811-812.


Andersson K-E. Are female lower urinary tract symptoms alleviated by alpha-adrenoreceptor antagonists? [commentary]. Nat Clin Pract Urol. 2008; 5(11):586-587.


Gratzke C, Jarajapu YPR, Christ GJ, Kaplan JR, Williams JK, Andersson K-E, Badlani G. Effects of long-term dietary soy treatment on female urethral morphology and function in ovariectomized nonhuman primates. J Urol. 2008; 180(5):2247-2253.


Gratzke C, Streng T, Waldkirch E, Sigl K, Stief CG, Andersson K, Hedlund P. Transient receptor potential A1 (TRPA1) ion channel activity in the human urethra--evidence for a functional role for TRPA1 in the outflow region [abstract]. Neurourol Urodyn. 2008; 27(7 Suppl):599-600.


Igawa Y, Aizawa N, Iijima K, Wyndaele JJ, Andersson K, Nishizawa O. Effects of intravesical capsaicin, resiniferatoxin and ATP on primary bladder afferent activity of the rat [abstract]. Neurourol Urodyn. 2008; 27(7 Suppl):709-711.


Zhang Y, McNeill E, Tian H, Soker S, Andersson K-E, Yoo JJ, Atala A. Urine derived cells are a potential source for urological tissue reconstruction. J Urol. 2008; 180(5):2226-2233.


Aizawa N, Ishizuka O, Ogawa T, Mizusawa H, Igawa Y, Nishizawa O, Andersson KE. Effects of natriuretic peptides on intracavernous pressure and blood pressure in conscious rats. J Sex Med. 2008; 5(10):2312-2317.


Andersson KE, Fullhase C [Fuellhase C], Soler R. Urothelial effects of oral agents for overactive bladder. Curr Urol Rep. 2008; 9(6):459-464.


Delo DM, Eberli D, Williams JK, Andersson K-E, Atala A, Soker S. Angiogenic gene modification of skeletal muscle cells to compensate for ageing-induced decline in bioengineered functional muscle tissue. BJU Int. 2008; 102(7):878-884.


Andersson K-E. Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial [editorial]. J Urol. 2007; 177(1):213.


Christ G, Andersson KE, Atala A. The future of bladder research: molecular profiling, new drug targets, gene therapy, and tissue engineering. Curr Urol Rep. 2007; 8(2):95-99.


Andersson KE. Functional role of the TRPV1 receptor in the urinary bladder [editorial comment on: Gevaert T et al. 2007. Neurourol Urodyn 26:424-432, Liu L et al. 2007. Neurourol Urodyn 26:433-438, and Gevaert T et al. 2007. Neurourol Urodyn 26:440-450]. Neurourol Urodyn. 2007; 26(3):451-453.


Gomez-Pinilla PJ, Gomez MF, Hedlund P, Sward K, Hellstrand P, Camello PJ, Pozo MJ, Andersson K-E. Effect of melatonin on age associated changes in guinea pig bladder function. J Urol. 2007; 177(4):1558-1561.


Lee T, Hedlund P, Newgreen D, Andersson K-E. Urodynamic effects of a novel EP1 receptor antagonist in normal rats and rats with bladder outlet obstruction. J Urol. 2007; 177(4):1562-1567.


Aboushwareb T, Jarajapu YPR, Blaha S, Hodges S, Turner C, Zhao W, Andersson K-E, Christ GJ. Mechanistic studies of detrusor over activity in male rats following partial urethral obstruction: implications to identification of novel therapeutics [abstract]. FASEB J. 2007; 21(6):A1356.


Aboushwareb T, Zho G, Turner C, Andersson K-E, Tar M, Melman A, Deng F-M, Sun T-T, Christ GJ. Urodynamic characterization of mice lacking uroplakin II or III [abstract]. FASEB J. 2007; 21(6):A1308.


Aboushwareb T, Andersson K-E, Christ GJ. Pharmacological studies of AGI-1140 in a rat model of erectile dysfunction [abstract]. FASEB J. 2007; 21(6):A1159-1160.


Andersson KE, Christ GJ. Regenerative pharmacology: the future is now. Mol Interv. 2007; 7(2):79-86.


Hodges S, Zhou G, Deng F-M, Abouschwareb T, Turner C, Andersson K-E, Santago P, Sun H, Christ GJ. Voiding patterns in uroplakin II knockout mice [abstract]. FASEB J. 2007; 21(6):A1301.


Zhao W, Machingal M, Turner C, Davies K, Andersson K-E, Melman A, Christ GJ. Threshold gene transfer with hSlo enhances sildenafil-induced erectile responses in 2 month streptozotocin(STZ)-diabetic rats [abstract]. FASEB J. 2007; 21(5):A420.


Bivalacqua TJ, Kendirci M, Champion HC, Hellstrom WJG, Andersson K-E, Hedlund P. Dysregulation of cGMP-dependent protein kinase 1 (PKG-1) impairs erectile function in diabetic rats: influence of in vivo gene therapy of PKG1alpha. BJU Int. 2007; 99(6):1488-1494.


Sjoqvist F, Eriksson L-O, Andersson K-E. Merck fellowships contribute to the continued growth of clinical pharmacology in Sweden. Eur J Cln Pharmacol. 2007; 63(3):229-231.


Aboushwareb TA, Zhou G, Turner C, Andersson KE, Tar M, Melman A, Deng FM, Sun TT, Christ GJ. Urodynamic studies in uroplakin II or III knockout (KO) mice [abstract]. J Urol. 2007; 177(4 Suppl):88.


Waldkirch ES, Uckert S, Langnase K, Richter K, Jonas U, Wolf G, Andersson K-E, Stief CG, Hedlund P. Immunohistochemical distribution of cyclic GMP-dependent protein kinase-1 in human prostate tissue. Eur Urol. 2007; 52(2):495-502.


Andersson KE, Gratzke C. Pharmacology of alpha1-adrenoceptor antagonists in the lower urinary tract and central nervous system. Nat Clin Pract Urol. 2007; 4(7):368-378.


Hedlund P, Streng T, Lee T, Andersson K-E. Effects of tolterodine on afferent neurotransmission in normal and resiniferatoxin treated conscious rats. J Urol. 2007; 178(1):326-331.


Andersson KE, Uckert S, Stief C, Hedlund P. Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS. Neurourol Urodyn. 2007; 26(Suppl 6):928-933.


Andersson KE. LUTS treatment: future treatment options. Neurourol Urodyn. 2007; 26(Suppl 6):934-947.


Christ GJ, Andersson KE. Rho-kinase and effects of Rho-kinase inhibition on the lower urinary tract. Neurourol Urodyn. 2007; 26(Suppl 6):948-954.


Andersson K, Kahler K, Ebinger U. Prevalence of cardiovascular co-morbidities in patients treated with antimuscarinics for overactive bladder (OAB) [abstract]. Neurourol Urodyn. 2007; 26(5):653-654.


Andersson K, Kahler K, Ebinger U. Heart rates in OAB patients prior to initiation of treatment with antimuscarinics [abstract]. Neurourol Urodyn. 2007; 26(5):654-655.


Abrams P, Andersson K-E. Muscarinic receptor antagonists for overactive bladder. BJU Int. 2007; 100(5):987-1006.


Andersson K-E, Olshansky B. Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerations. BJU Int. 2007; 100(5):1007-1014.


Hipp J, Andersson K-E, Kwon TG, Kwak EK, Yoo J, Atala A. Microarray analysis of exstrophic human bladder smooth muscle. BJU Int. 2007; 101(1):100-105.


Albrecht K, Uckert S, Oelke M, Andersson K-E, Jonas U, Troger H-D, Hedlund P. Immunohistochemical distribution of cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human vagina: a potential forensic value?. J Forensic Leg Med. 2007; 14(5):270-274.


Abrams P, Andersson K-E, Buccafusco JJ, Chapple C, de Groat WC, Fryer AD, Kay G, Laties A, Nathanson NM, Pasricha PJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol. 2006; 148(5):565-578.


Andersson KE. Treatment-resistant detrusor overactivity--underlying pharmacology and potential mechanisms. Int J Clin Pract Suppl. 2006; 151():8-16.


Finney SM, Andersson K-E, Gillespie JI, Stewart LH. Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions?. BJU Int. 2006; 98(3):503-507.


Drake M, Gillespie J, Hedlund P, Harvey I, Lagou M, Andersson K-E. Muscarinic stimulation of the rat isolated whole bladder: pathophysiological models of detrusor overactivity. Auton Autacoid Pharmacol. 2006; 26(3):261-266.


Lagou M, De Vente J, Kirkwood TB, Hedlund P, Andersson K-E, Gillespie JI, Drake MJ. Location of interstitial cells and neurotransmitters in the mouse bladder. BJU Int. 2006; 97(6):1332-1337.


Oelke M, Hedlund P, Albrecht K, Ellinghaus P, Stief CG, Jonas U, Andersson K-E, Uckert S. Expression of cAMP and cGMP-phosphodiesterase isoenzymes 3, 4, and 5 in the human clitoris: immunohistochemical and molecular biology study. Urology. 2006; 67(5):1111-1116.


Pandita RK, Ronn LCB, Jensen BS, Andersson K-E. Urodynamic effects of intravesical administration of the new small/intermediate conductance calcium activated potassium channel activator NS309 in freely moving, conscious rats. J Urol. 2006; 176(3):1220-1224.


Streng T, Hedlund P, Talo A, Andersson K-E, Gillespie JI. Phasic non-micturition contractions in the bladder of the anaesthetized and awake rat. BJU Int. 2006; 97(5):1094-1101.


Uckert S, Oelke M, Stief CG, Andersson K-E, Jonas U, Hedlund P. Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol. 2006; 49(4):740-745.


Schroder A, Colli E, Maggi M, Andersson K-E. Effects of a vitamin D3 analogue in a rat model of bladder outlet obstruction. BJU Int. 2006; 98(3):637-642.


Uckert S, Hedlund P, Andersson K-E, Truss MC, Jonas U, Stief CG. Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future. Eur Urol. 2006; 50(6):1194-1207.


Werkstrom V, Svensson A, Andersson K-E, Hedlund P. Phosphodiesterase 5 in the female pig and human urethra: morphological and funcitonal aspects. BJU Int. 2006; 98(2):414-423.
All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Back To Top
Last Updated 12/31/2011
Loading...
Quick Reference
Request an Appointment
New Patients
336-716-WAKE
888-716-WAKE
Existing patients may contact the clinic directly.
Locate Faculty

e.g., "allergy," "diabetes"

US News Best Hospital AwardANCC Magnet Association AwardBest Doctors 2011-2012 AwardThe Joint Commission National Quality ApprovalConsumer Choice #1 Award 2011-2102US News Best Medical Schools 2011 Award
Loading...

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.